New GLP-1 Pill Offers Weight Loss With Fewer Restrictions Amidst Accessibility Concerns
The US Food and Drug Administration has approved Foundayo, Eli Lilly’s second GLP-1 pill for weight loss, expanding treatment options for obesity. Unlike the previously approved Wegovy pill, Foundayo offers greater convenience by allowing intake at any time of day without food or water restrictions. This new pill, which demonstrated an average weight loss of 12% in clinical trials, aims to improve access and affordability, with Lilly offering programs to reduce out-of-pocket costs for eligible patients. Foundayo joins a growing class of GLP-1 medications that mimic a hormone regulating appetite and digestion, though common gastrointestinal side effects and the need for long-term use remain considerations.
John Q. Hosedrinker